Advertisement

Prognostic value of thrombocytosis in patients undergoing surgery for colorectal cancer with synchronous liver metastases

  • C. PedrazzaniEmail author
  • G. Turri
  • G. Mantovani
  • C. Conti
  • R. Ziello
  • S. Conci
  • T. Campagnaro
  • A. Ruzzenente
  • A. Guglielmi
Research Article
  • 57 Downloads

Abstract

Purpose

The purpose of this study was to evaluate the prognostic role of thrombocytosis in patients with synchronous colorectal liver metastases (CRLM).

Methods

Retrospective analysis of patients who underwent surgery for colorectal cancer with synchronous CRLM at the Division of General and Hepatobiliary Surgery, University of Verona Hospital Trust between 2005 and 2016.

Results

One hundred and ninety-six patients met the inclusion criteria. High platelet count (H-PC) was found in 32%, and it was associated with a higher rate of palliative surgery (p < 0.001), extra-hepatic metastases (p < 0.001), bilobar liver disease (p = 0.007), presence of more than three metastases (p = 0.005), biggest metastasis larger than 5 cm (p < 0.001), and CEA level higher than 200 ng/mL (p = 0.035). H-PC was significantly associated with poorer 5-year overall survival (14.3% vs. 34.3%; p = 0.001). At the multivariate analysis on R0-1 cases, platelet count resulted the only independent predictor of survival (HR 2.07, p = 0.036).

Conclusion

H-PC correlates with the main negative clinical–pathological factors in patients with synchronous CRLM, as well as with overall survival. Moreover, it was the only independent prognostic factor in those who underwent curative surgery.

Keywords

Colorectal cancer Liver metastasis Thrombocytosis Platelet count Prognosis 

Abbreviations

CRC

Colorectal cancer

CRLM

Colorectal liver metastasis

CEA

Carcinoembryonic antigen

PC

Platelet count

L-PC

Low platelet count

H-PC

High platelet count

PPV

Positive predictive value

NPV

Negative predictive value

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The latest revision of the Helsinki Declaration and the Oviedo Declaration are the basis for the ethical conduct of the study. Ethical approval was obtained by the ethics committee of the University of Verona Hospital Trust with the reference number “42763 (CRINF-1034 CESC)”.

Informed consent

Achievement of informed consent from all patients was required to enter the study.

References

  1. 1.
    Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.CrossRefGoogle Scholar
  2. 2.
    Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93:465–74.  https://doi.org/10.1002/bjs.5278.CrossRefGoogle Scholar
  3. 3.
    Sandström P, Røsok BI, Sparrelid E, Larsen PN, Larsson AL, Lindell G, et al. ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis. Ann Surg. 2017;267:1.Google Scholar
  4. 4.
    Torzilli G, Adam R, Viganò L, Imai K, Goransky J, Fontana A, et al. Surgery of colorectal liver metastases: pushing the limits. Liver Cancer. 2016;6:80–9.CrossRefGoogle Scholar
  5. 5.
    Adam R, Yi B, Innominato PF, Barroso E, Laurent C, Giuliante F, et al. Resection of colorectal liver metastases after second-line chemotherapy: Is it worthwhile? A LiverMetSurvey analysis of 6415 patients. Eur J Cancer. 2017;78:7–15.CrossRefGoogle Scholar
  6. 6.
    Akgül Ö, Çetinkaya E, Ersöz Ş, Tez M. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol 2014;20:6113–22.Google Scholar
  7. 7.
    Mattar RE, Al-Alem F, Simoneau E, Hassanain M. Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection. World J Gastroenterol. 2016;22:567–81.CrossRefGoogle Scholar
  8. 8.
    Viganò L, Capussotti L, Lapointe R, Barroso E, Hubert C, Giuliante F, et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6025 patients. Ann Surg Oncol. 2014;21:1276–86.  https://doi.org/10.1245/s10434-013-3421-8.CrossRefGoogle Scholar
  9. 9.
    Rees M, Tekkis PP, Welsh FKS, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.CrossRefGoogle Scholar
  10. 10.
    Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254–62.CrossRefGoogle Scholar
  11. 11.
    Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, Makuuchi M. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis. Arch Surg. 2007;142:269.  https://doi.org/10.1001/archsurg.142.3.269.CrossRefGoogle Scholar
  12. 12.
    Pedrazzani C, Mantovani G, Fernandes E, Bagante F, Luca Salvagno G, Surci N, et al. Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep. 2017;7:1–10.CrossRefGoogle Scholar
  13. 13.
    Kozak MM, von Eyben R, Pai JS, Anderson EM, Welton ML, Shelton AA, et al. The prognostic significance of pretreatment hematologic parameters in patients undergoing resection for colorectal cancer. Am J Clin Oncol. 2017;40:405–12.CrossRefGoogle Scholar
  14. 14.
    Dell’Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018;29:924–30.CrossRefGoogle Scholar
  15. 15.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A. AJCC cancer staging manual, 7th ed. 2010.Google Scholar
  16. 16.
    Pedrazzani C, Lauka L, Sforza S, Ruzzenente A, Nifosì F, Delaini GG, et al. Management of nodal disease from colon cancer in the laparoscopic era. Int J Colorectal Dis. 2015;30:303–14.CrossRefGoogle Scholar
  17. 17.
    Pang YY, Strasberg SM. The Brisbane 2000 terminology of liver anatomy and resections. HPB. 2000;2:333–9.CrossRefGoogle Scholar
  18. 18.
    Agha RA, Borrelli MR, Vella-Baldacchino M, Thavayogan R, Orgill DP, Pagano D, et al. The STROCSS statement: strengthening the reporting of cohort studies in surgery. Int J Surg. 2017;46:198–202.CrossRefGoogle Scholar
  19. 19.
    Bensalah K, Leray E, Fergelot P, Rioux-Leclercq N, Tostain J, Guillé F, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol. 2006;175:859–63.CrossRefGoogle Scholar
  20. 20.
    Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S, et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol. 2002;9:287–91.CrossRefGoogle Scholar
  21. 21.
    Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H, et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg. 2004;198:737–41.CrossRefGoogle Scholar
  22. 22.
    Guo T, Krzystanek M, Szallasi Z, Szallasi A. Thrombocytosis portends adverse prognostic significance in patients with stage II colorectal carcinoma. F1000Research. 2014;3:180.CrossRefGoogle Scholar
  23. 23.
    Cravioto-Villanueva A, Luna-Perez P, Gutierrez-de la Barrera M, Martinez-Gómez H, Maffuz A, Rojas-Garcia P, et al. Thrombocytosis as a predictor of distant recurrence in patients with rectal cancer. Arch Med Res. 2012;43:305–11.CrossRefGoogle Scholar
  24. 24.
    Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, et al. Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013;44:293–304.CrossRefGoogle Scholar
  25. 25.
    Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 1968;61:46–52.CrossRefGoogle Scholar
  26. 26.
    Pearlstein E, Ambrogio C, Karpatkin S. Effect of antiplatelet antibody on the development of pulmonary metastases following injection of CT26 colon adenocarcinoma, Lewis lung carcinoma, and B16 amelanotic melanoma tumor cells into mice. Cancer Res. 1984;44:3884–7.Google Scholar
  27. 27.
    Kawai K, Watanabe T. Colorectal cancer and hypercoagulability. Surg Today. 2014;44:797–803.CrossRefGoogle Scholar
  28. 28.
    Poggi A, Stella M, Donati MB. The importance of blood cell-vessel wall interactions in tumour metastasis. Baillieres Clin Haematol. 1993;6:731–52.CrossRefGoogle Scholar
  29. 29.
    Placke T, Kopp H-G, Salih HR. The wolf in sheep’s clothing: platelet-derived “pseudo self” impairs cancer cell “missing self” recognition by NK cells. Oncoimmunology. 2012;1:557–9.CrossRefGoogle Scholar
  30. 30.
    Seretis C, Youssef H, Chapman M. Hypercoagulation in colorectal cancer: What can platelet indices tell us? Platelets. 2015;26:114–8.CrossRefGoogle Scholar
  31. 31.
    Pedrazzani C, Mantovani G, Salvagno GL, Baldiotti E, Ruzzenente A, Iacono C, et al. Elevated fibrinogen plasma level is not an independent predictor of poor prognosis in a large cohort of Western patients undergoing surgery for colorectal cancer. World J Gastroenterol. 2016;22:9994–10001.CrossRefGoogle Scholar
  32. 32.
    Kandemir E, Mayadagli A, Karagoz B, Bilgi O, Turken O, Yaylaci M. Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res. 2005;33:228–35.  https://doi.org/10.1177/147323000503300211.CrossRefGoogle Scholar
  33. 33.
    Toiyama Y, Inoue Y, Kawamura M, Kawamoto A, Okugawa Y, Hiro J, et al. Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. Int Surg. 2015;100:199–207.CrossRefGoogle Scholar
  34. 34.
    Leitch EF, Chakrabarti M, Crozier JEM, McKee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266–70.CrossRefGoogle Scholar
  35. 35.
    Lee YS, Suh KW, Oh SY. Preoperative thrombocytosis predicts prognosis in stage II colorectal cancer patients. Ann Surg Treat Res. 2016;90:322–7.CrossRefGoogle Scholar
  36. 36.
    Kulik U, Schrem H, Bektas H, Klempnauer J, Lehner F. Prognostic relevance of hematological profile before resection for colorectal liver metastases. J Surg Res. 2016;206:498–506.CrossRefGoogle Scholar
  37. 37.
    Nyasavajjala SM, Runau F, Datta S, Annette H, Shaw AG, Lund JN. Is there a role for pre-operative thrombocytosis in the management of colorectal cancer? Int J Surg. 2010;8:436–8.CrossRefGoogle Scholar
  38. 38.
    Rao X-D, Zhang H, Xu Z-S, Cheng H, Shen W, Wang X-P. Poor prognostic role of the pretreatment platelet counts in colorectal cancer. Medicine. 2018;97:e10831.CrossRefGoogle Scholar
  39. 39.
    Del Prete M, Giampieri R, Loupakis F, Prochilo T, Salvatore L, Faloppi L, et al. Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. Oncotarget. 2015;6:33982–92.Google Scholar
  40. 40.
    Neal CP, Cairns V, Jones MJ, Masood MM, Nana GR, Mann CD, et al. Prognostic performance of inflammation-based prognostic indices in patients with resectable colorectal liver metastases. Med Oncol. 2015;32:144.  https://doi.org/10.1007/s12032-015-0590-2.CrossRefGoogle Scholar
  41. 41.
    Kronborg CS, Jensen AR. Prognostic factors for overall survival in metastatic colorectal cancer using a stop-and-go FLIRI-based treatment strategy. Int J Colorectal Dis. 2015;30:1059–65.  https://doi.org/10.1007/s00384-015-2264-0.CrossRefGoogle Scholar
  42. 42.
    Neal CP, Mann CD, Sutton CD, Garcea G, Ong SL, Steward WP, et al. Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer. 2009;45:56–64.CrossRefGoogle Scholar
  43. 43.
    Jósa V, Krzystanek M, Vass T, Lang T, Juhász V, Szilágyi K, et al. Thrombocytosis of liver metastasis from colorectal cancer as predictive factor. Pathol Oncol Res. 2015;21:991–7.  https://doi.org/10.1007/s12253-015-9925-8.CrossRefGoogle Scholar
  44. 44.
    Pawlik TM, Vauthey J-N. Surgical margins during hepatic surgery for colorectal liver metastases: complete resection not millimeters defines outcome. Ann Surg Oncol. 2008;15:677–9.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2019

Authors and Affiliations

  1. 1.Division of General and Hepatobiliary Surgery, Department of Surgical Sciences, Dentistry, Gynecology and PediatricsUniversity of VeronaVeronaItaly
  2. 2.Division of General and Hepatobiliary SurgeryUniversity Hospital “G.B. Rossi”VeronaItaly

Personalised recommendations